Skip to main content
Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
83.30
-4.45 (-5.07%)
At close: Nov 13, 2026, 4:00 PM EST
79.56
-3.74 (-4.49%)
After-hours: Nov 13, 2026, 7:30 PM EST

Inhibrx Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
21.30.21.81.327.23
Revenue Growth
42.86%550.00%-88.89%36.88%-81.81%-43.89%
Gross Profit
-111.03-111.73-177.64-189.84-100.29-64.21
Operating Income
-125.73-135.03-222.29-219.19-115.32-76.56
Net Income
-141.66-140.061,688-241.36-115.33-81.77
Earnings Per Share
-9.06-9.04112.62-20.48-2.88-2.15
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
199.47124.22152.6277.920131.3
Total Debt
276.7107.018.05210.145.0370.47
Net Cash (Debt)
-77.2317.21144.5567.78-5.0360.83
Net Cash Growth
--88.09%113.25%---38.81%
Net Cash Per Share
-4.941.119.655.75-0.131.60

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
--129.79-194.41-193.31-90.81-
Capital Expenditures
--0.03-2.6-4.59-0.69-
Free Cash Flow
--129.83-197.01-197.9-91.5-
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-6286.70%-10386.54%-111143.50%-12176.94%-8769.81%-1058.83%
Pretax Margin
-7082.75%-10773.31%843787.00%-13408.78%-8769.73%-1130.77%
Profit Margin
-7082.90%-10773.46%843786.00%-13408.94%-8769.96%-1130.80%
FCF Margin
--9986.54%-98503.00%-10994.56%-6957.95%-

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--0.13---
Forward PE
-0.200.20---
PS Ratio
612.99883.811114.65---